menù
Phase: Phase II-III clinical trials
Principal Investigator: Dott.ssa Guidetti Anna
Main Facility: Haematology
Drug: Ruxolitinib
Principal Investigator: Associate Professor Licitra Lisa Francesca Linda
Main Facility: Medical Oncology 3 – Head and Neck Cancers
Drug: MEDI5752
Principal Investigator: Dott.ssa Bianchi Giulia Valeria
Main Facility: Medical Oncology 1
Drug: Giredestrant + inibitore di CDK4/6 Fulvestrant + inibitore di CDK4/6
Phase: Phase III clinical trials
Main Facility: Breast Medical Oncology
Drug: Pumitamig (indicato anche come BNT327 o PM8002)
Drug: Arm A: inavolisib + letrozolo + palbociclib o ribociclib Arm B: placebo + letrozolo + palbociclib o ribociclib
Drug: RO7198574 + Inavolisib RO7198574 + Placebo
Principal Investigator: Prof. Corradini Paolo
Drug: AZD0120
Principal Investigator: Dr. Beninato Teresa
Main Facility: Thoracic Oncology Unit
Drug: BNT327
Phase: Phase II clinical trials
Principal Investigator: Dr. Pietrantonio Filippo
Main Facility: Gastrointestinal Oncology
Drug: Irinotecan + cetuximab vs. trifluridina/tipiracil + bevacizumab
Principal Investigator: Prof. Vernieri Claudio
Drug: Inavolisib + Fulvestrant + Ribociclib vs Placebo + Fulvestrant + Ribociclib
Drug: KTE-X-19 (brexucabtagene autoleucel)
Phase: Phase I-II clinical trials
Principal Investigator: Dott.ssa Verzoni Elena
Main Facility: Genitourinary Medical Oncology
Drug: AMO959 e AAA617 (Lutetium (177Lu) vipivotide tetraxetan)
Principal Investigator: Dr. Damian Silvia
Drug: ALE.P03
Principal Investigator: Dott.ssa Indini Alice
Drug: ALE.P02
Principal Investigator: Dott.ssa Cresta Sara
Drug: BNT326 BNT327
Phase: Phase I clinical trials
Main Facility: Nuclear Medicine
Drug: [68Ga]Ga-OncoFAP (OncoFAP-DOTAGA marcato con 68Ga) [177Lu]Lu-OncoFAP-23 (OncoFAP-23 marcato con 177Lu) L19-IL2
Principal Investigator: Dr. Brambilla Marta
Drug: V940 (mRNA-4157)
Drug: MK-2870
Principal Investigator: Dott.ssa Ducceschi Monika
Main Facility: Gynecologic Surgical Oncology
Drug: MK-2870, also known as Sacituzumab tirumotecan
Drug: BMS-986393 (Arlocabtagene Autoleucel)
Sign up for our newsletter to stay informed about news, events, and updates from the Institute
Subscribe